The prevalence of attention-deficit/hyperactivity disorder (ADHD) diagnoses in the United States increased significantly from 1997 to 2016, reports a new study.


Rakesh Jain

Have cell phones and easy access to technology increased the incidence of attention-deficit/hyperactivity disorder (ADHD)? Find out from Psych Congress cochair Rakesh Jain, MD, MPH.

A brain-computer-interface (BCI)-based attention-training game appears to alter connectivity of some brain networks in children with attention-deficit/hyperactivity disorder (ADHD), researchers report.

For short-term treatment of attention deficit hyperactivity disorder (ADHD), methylphenidate is the first-line drug of choice for children, and amphetamines are best for adults, according to authors of a network meta-analysis.

Julie Carbray

Psych Congress Steering Committee member Julie Carbray, PhD, FPMHNP, PMHCNS, discusses research on links between nutrition and attention-deficit/hyperactivity disorder (ADHD) symptoms in children.

The US Food and Drug Administration has approved the first stimulant medication to be taken in the evening for the treatment of attention-deficit/hyperactivity disorder (ADHD), Ironshore Pharmaceuticals announced.



Thomas Brown, PhD; Emuella Flood, BA; Phil Sarocco, BPharm, MSc; Norman Atkins, Jr., MBA, PhD; Alexandra Khachatryan, MPH
Stephen Faraone, PhD; Rick Nullmeier, BA; Norberto DeSousa, MA; Floyd Sallee, MD, PhD; Bev Incledon, PhD; Timothy Wilens, MD
Robert Goldman, PhD; Ann Childress, MD; Sharon Wigal, PhD; Seth Hopkins, PhD; Kenneth Koblan, PhD; Kaushik Sarma, MD; Xiaohai Wan, PhD; Antony Loebel, MD
Brigitte Robertson, MD; Ming Yu, MD, PhD; Brian Yan, PhD; Michael Greenbaum, MD; Lenard Adler, MD